Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)

Aragón, Isabel M.; Cendón, Ylenia; Lorenté, David; Mejorada, R. Lozano; Laorden, N. Romero; Medina-Colmenero, A.; Puente, Javier; Villatoro, R.; Estévez, Sergio Vázquez; Piulats, Josep M.; Laínez, Núria; Fernández-Parra, E.; Alba, Aránzazu Gonzalez del; Jorge, Alexandra; Olmos, B.; Rivera, L.; Pacheco, M.I.; Hidalgo, Daniel; Castro, E.

doi:10.1093/annonc/mdz248.038

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, a number of studies have focused on the association between single nucleotide polymorphisms in androgen-related genes and prognoses. Several single nucleotide polymorphisms also have impacts on castration-resistant prostate cancer progression and overall patient survival (Aragon, Cendon, Lorente, & Mejorada, 2019). (Fujimoto, Shiota, Tomisaki, & Minato, 2017;Shiota et al, 2017).…”

Section: Gene Polymorphismsmentioning

confidence: 99%

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Wang

Chen

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

Prostate cancer is the second most common malignancy in men and androgen deprivation therapy is the first-line therapy. However, most cases will eventually develop castration-resistant prostate cancer after androgen deprivation therapy treatment. Enzalutamide is a second-generation androgen receptor antagonist approved by the Food and Drug Administration to treat patients with castrationresistant prostate cancer. Unfortunately, patients receiving enzalutamide treatment will ultimately develop resistance via various complicated mechanisms. This review examines the emerging information on these resistance mechanisms, including androgen receptor-related signalling pathways, glucocorticoid receptor-related pathways and metabolic effects. Notably, lineage plasticity and phenotype switching, gene polymorphisms and the relationship between microRNAs and drug resistance are addressed. Furthermore, potential therapeutic strategies for enzalutamideresistant castration-resistant prostate cancer treatment are suggested, which can help discover more effective and specific regimens to overcome enzalutamide resistance.

show abstract

Section: Gene Polymorphismsmentioning

confidence: 99%

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Wang

Chen

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…In recent years, a number of studies have focused on the association between single nucleotide polymorphisms (SNPs) in androgen-related genes and prognoses. Several SNPs also had impacts on CRPC progression and overall patient survivalc (Aragon, Cendon et al, 2019). Despite their roles in tumour development, there was a link between SNPs and Enz resistance.…”

Section: Genepolymorphismsmentioning

confidence: 99%

Mechanisms of Enzalutamide Resistance in Castration-Resistant Prostate Cancer and Therapeutic Strategies to Overcome It

Wang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common malignancy in men, and androgen deprivation therapy (ADT) is the first-line therapy. However, most cases will eventually develop into castration-resistant prostate cancer (CRPC) after ADT treatment. Enzalutamide (Enz) is a second-generation androgen receptor inhibitor approved by the Food and Drug Administration to treat patients with CRPC. Unfortunately, patients receiving Enz treatment will ultimately develop resistance via various complicated mechanisms. In this review, we introduce the emerging information on resistance mechanisms, including androgen receptorrelated signalling pathways, glucocorticoid receptor-related pathways, and metabolic mechanisms. Notably, lineage plasticity and phenotype switching, gene polymorphisms, and the relationship between microRNAs and drug resistance are addressed. Furthermore, potential therapeutic strategies for Enz-resistant CRPC treatment are suggested, which can help in the discovery of more effective and specific regimens to overcome Enz resistance.

show abstract

Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours

Crucitta

Cucchiara

Mathijssen

et al. 2022

Cancer Treatment Reviews

View full text Add to dashboard Cite

Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)

Cited by 4 publications

References 0 publications

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Mechanisms of Enzalutamide Resistance in Castration-Resistant Prostate Cancer and Therapeutic Strategies to Overcome It

Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours

Contact Info

Product

Resources

About